FDA Approves First Drug to Treat Rare Metabolic Disorder
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is …
Read More